Neurodegenrative and inflammatory disorders
You may also be interested in...
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.
One stool sample kit and three serology tests are identified in the agency’s latest warning on OTC sales of unapproved COVID-19 tests. One of the warned firm continues offering sales of its violative product.
Firms including Depuy Synthes, Medtronic Inc., and Zimmer Biomet Holdings Inc., spent thousands of dollars lobbying Congress last winter.